RESUMO
Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.
Assuntos
Antipsicóticos/síntese química , Antipsicóticos/isolamento & purificação , Descoberta de Drogas/tendências , Esquizofrenia/tratamento farmacológico , Animais , Antipsicóticos/química , Modelos Animais de Doenças , Descoberta de Drogas/métodos , Epigenômica/métodos , Estudo de Associação Genômica Ampla , Humanos , Modelos Biológicos , Terapia de Alvo Molecular/métodos , Terapia de Alvo Molecular/tendências , New York , Pesquisa/tendências , Projetos de Pesquisa , Esquizofrenia/epidemiologia , Esquizofrenia/genéticaRESUMO
We predict an enormous order-dependent quantum enhancement of thermoelectric effects in the vicinity of higher-order interferences in the transmission spectrum of a nanoscale junction. Single-molecule junctions based on 3,3'-biphenyl and polyphenyl ether (PPE) are investigated in detail. The nonequilibrium thermodynamic efficiency and power output of a thermoelectric heat engine based on a 1,3-benzene junction are calculated using many-body theory and compared to the predictions of the figure-of-merit ZT.